Rein Therapeutics Reports Positive LTI-03 Study Results in IPF Patients.

Rein Therapeutics, a biopharmaceutical company, has announced the posting of a preprint on medRxiv detailing findings from a randomized dose-escalation study of its lead drug candidate, LTI-03, in idiopathic pulmonary fibrosis (IPF). The study assessed the safety, pharmacokinetics, and biological activity of inhaled LTI-03 in IPF patients. The authors found that LTI-03 was generally well tolerated, with no serious adverse events reported. The study provides preliminary data supporting the potential of LTI-03 as a treatment for IPF.